[Treatment of chronic heart failure in patients with mitral and aortic valve defects of rheumatic origin].
OBJECTIVE
To evaluate efficiency of using ACE inhibitor (capoten) and beta-blocker (atenolol) in diverse mitral and aortic valve defects (MVD and AVD, respectively) of rheumatic etiology complicated by chronic cardiac failure (CCF) of the first and second stages.


METHODS
The trial enrolled 41 patients with MVD and 21 patients with AVD of rheumatic etiology. 60 of them had CCF. In cross-over study 38 patients with MVD and 21 with AVD received capoten (6.25 mg/day) for 7 days while 33 patients with MVD were treated with atenolol. Exercise tolerance (ET) and hemodynamics (echo-CG) were examined before and after the treatment.


RESULTS
Hemodynamic parameters and ET improved after capoten and atenolol treatment in patients with MVD or AVD and in complex disease (stenosis and insufficiency) with predominant insufficiency. No significant hemodynamic changes were induced by the above drugs in patients with isolated mitral and aortic stenoses.


CONCLUSIONS
Capoten vs atenolol has more potent positive effect in CCF patients with MVD or AVD.
Bagirova
G G
GG
Batalina
M V
MV
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001022:Aortic Valve Insufficiency / Q000150:complications* / Q000503:physiopathology; D001262:Atenolol / Q000627:therapeutic use*; D002216:Captopril / Q000627:therapeutic use*; D004452:Echocardiography; D005080:Exercise Test; D005260:Female; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics; D006801:Humans; D008297:Male; D008875:Middle Aged; D008944:Mitral Valve Insufficiency / Q000150:complications* / Q000503:physiopathology; D008946:Mitral Valve Stenosis / Q000150:complications* / Q000503:physiopathology; D012214:Rheumatic Heart Disease / Q000150:complications*
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001262:Atenolol; D002216:Captopril